{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:43:58Z","timestamp":1780631038147,"version":"3.54.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PTC Therapeutics International Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Aromatic <jats:sc>l<\/jats:sc>-amino acid decarboxylase (AADC) deficiency is a rare neurological disorder associated with a range of symptoms and functional impairments. The aim of this study was to describe the experience of AADC deficiency across five different motor milestone health states.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Qualitative interviews were conducted with caregivers of individuals with AADC deficiency in Italy, Spain, Portugal and the United States. An interview guide was developed with input from clinical experts and caregivers, and explored the symptoms and impacts of AADC deficiency. Interviews were conducted by telephone and were recorded and transcribed. Data were analysed using thematic analysis and the symptoms and impacts were compared across health states.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fourteen caregivers took part, who provided care to 13 individuals with AADC deficiency aged 1\u201315\u00a0years. Six individuals were in the \u2018no motor function\u2019 health state, one in the \u2018sitting unsupported\u2019 health state, one in the \u2018standing\/stepping when fully supported\u2019 health state and five in the \u2018walking with minimal support\u2019 health state. The results highlight a substantial impact of AADC deficiency, even among those who were able to walk with minimal support. Overall, those with better motor function also had better functional hand use, communication skills, ability to eat and perform other activities independently, and interact with their peers. The burden of caring was high across all health states, but caregivers of individuals in the walking health state were better able to participate in social and leisure activities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Individuals with higher levels of motor function had less severe symptoms and were better able to perform their daily, leisure and social activities. Treatments which improve motor function have the potential to improve other aspects of the lives of individuals with AADC deficiency and their caregivers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02274-0","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T09:03:29Z","timestamp":1647853409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Symptoms and impacts of aromatic l-amino acid decarboxylase (AADC) deficiency among individuals with different levels of motor function"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4874-0334","authenticated-orcid":false,"given":"Kate","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Skrobanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Buesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Acaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"2274_CR1","unstructured":"Whitehead N, Schu M, Erickson SW, Croxford J, Peters MHK. Estimated prevalence of aromatic l-amino acid decarboxylase (AADC) deficiency in the United States, European Union, and Japan. In: Annual Congress of the European Society of gene and cell therapy. Lausanne; 2018."},{"key":"2274_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pediatrneurol.2019.11.022","volume":"106","author":"K Hyland","year":"2020","unstructured":"Hyland K, Reott M. Prevalence of aromatic l-amino acid decarboxylase deficiency in at-risk populations. Pediatr Neurol. 2020;106:38\u201342.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"2274_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2016.05.011","volume":"118","author":"YH Chien","year":"2016","unstructured":"Chien YH, Chen PW, Lee NC, Hsieh WS, Chiu PC, Hwu WL, et al. 3-O-methyldopa levels in newborns: result of newborn screening for aromatic l-amino-acid decarboxylase deficiency. Mol Genet Metab. 2016;118(4):259\u201363.","journal-title":"Mol Genet Metab"},{"key":"2274_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.parkreldis.2016.11.012","volume":"36","author":"E Barow","year":"2017","unstructured":"Barow E, Schneider SA, Bhatia KP, Ganos C. Oculogyric crises: etiology, pathophysiology and therapeutic approaches. Parkinsonism Relat Disord. 2017;36:3\u20139.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"2274_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/jimd.12247","volume":"43","author":"TS Pearson","year":"2020","unstructured":"Pearson TS, Gilbert L, Opladen T, Garcia-Cazorla A, Mastrangelo M, Leuzzi V, et al. AADC deficiency from infancy to adulthood: symptoms and developmental outcome in an international cohort of 63 patients. J Inherit Metab Dis. 2020;43(5):1121\u201330.","journal-title":"J Inherit Metab Dis"},{"key":"2274_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13023-016-0522-z","volume":"12","author":"T Wassenberg","year":"2017","unstructured":"Wassenberg T, Molero-Luis M, Jeltsch K, Hoffmann GF, Assmann B, Blau N, et al. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. Orphanet J Rare Dis. 2017;12:12.","journal-title":"Orphanet J Rare Dis"},{"key":"2274_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13052-021-00954-4","volume":"47","author":"C Fusco","year":"2021","unstructured":"Fusco C, Leuzzi V, Striano P, Battini R, Burlina A, Belcastro V, et al. Aromatic l-amino acid decarboxylase (AADC) deficiency: results from an Italian modified Delphi consensus. Ital J Pediatr. 2021;47:13.","journal-title":"Ital J Pediatr"},{"key":"2274_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2352-4642(17)30125-6","volume":"1","author":"YH Chien","year":"2017","unstructured":"Chien YH, Lee NC, Tseng SH, Tai CH, Muramatsu S, Byrne BJ, et al. Efficacy and safety of AAV2 gene therapy in children with aromatic l-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial. Lancet Child Adolesc Health. 2017;1:265\u201373.","journal-title":"Lancet Child Adolesc Health"},{"key":"2274_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/brain\/awy331","volume":"142","author":"K Kojima","year":"2019","unstructured":"Kojima K, Nakajima T, Taga N, Miyauchi A, Kato M, Matsumoto A, et al. Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency. Brain. 2019;142:322\u201333.","journal-title":"Brain"},{"key":"2274_CR10","doi-asserted-by":"publisher","first-page":"134ra61","DOI":"10.1126\/scitranslmed.3003640","volume":"4","author":"WL Hwu","year":"2012","unstructured":"Hwu WL, Muramatsu SI, Tseng SH, Tzen KY, Lee NC, Chien YH, et al. Gene therapy for aromatic l-amino acid decarboxylase deficiency. Sci Transl Med. 2012;4:134ra61.","journal-title":"Sci Transl Med."},{"key":"2274_CR11","doi-asserted-by":"crossref","unstructured":"Simons C, Paris J, Bennison CBK. Global symptom improvement for patients with aromatic L-amino acid decarboxylase deficiency using individual participant data. In: Proceedings of the International Society of Pharmacoepidemiology; 2021 Aug 23\u201325.","DOI":"10.1016\/j.jval.2020.08.1747"},{"key":"2274_CR12","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1080\/03007995.2021.1932449","volume":"37","author":"K Williams","year":"2021","unstructured":"Williams K, Skrobanski H, Werner C, O\u2019Neill S, Buesch K, Acaster S. Symptoms and impact of aromatic l-amino acid decarboxylase (AADC) deficiency: a qualitative study and the development of a patient-centred conceptual model. Curr Med Res Opin. 2021;37:1353\u201361.","journal-title":"Curr Med Res Opin"},{"key":"2274_CR13","doi-asserted-by":"publisher","first-page":"S714","DOI":"10.1016\/j.jval.2020.08.1871","volume":"23","author":"A Smith","year":"2020","unstructured":"Smith A, Hanbury A, Whitty J, Buesch K. PRO135 a discrete choice experiment to derive health state utilities for aromatic l-amino acid decarboxylase (AADC) deficiency in the United Kingdom. Value Health. 2020;23:S714.","journal-title":"Value Health"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02274-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02274-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02274-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T09:06:23Z","timestamp":1647853583000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02274-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2274"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02274-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"3 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was submitted for ethical review by the WIRB-Copernicus Group Independent Review Board and was granted an exemption (tracking number: #1-1327023-1). All participants provided informed consent before taking part.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants provided their consent for their data to be published in peer-reviewed academic journals before taking part in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Kate Williams, Hanna Skrobanski and Sarah Acaster are employees of Acaster Lloyd Consulting Ltd. Katharina Buesch is an employee of PTC Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}